TY - JOUR AB - Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5x107 to 1x108. Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immuno­suppressive drugs were used post‑first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP. AD - Department of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China Jilin Tuhua Bioengineering Company Ltd., Siping, Jilin 136000, P.R. China Department of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122, P.R. China Department of Vascular Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, P.R. China AU - Wang,Xiaohua AU - Yin,Xiaoguang AU - Sun,Wei AU - Bai,Jin AU - Shen,Yawen AU - Ao,Qiang AU - Gu,Yongquan AU - Liu,Ying DA - 2017/05/01 DO - 10.3892/etm.2017.4229 EP - 2258 IS - 5 JO - Exp Ther Med KW - chronic immune thrombocytopenic purpura human umbilical cord-derived mesenchymal stem cells intravenous infusion safety efficacy PY - 2017 SN - 1792-0981 1792-1015 SP - 2255 ST - Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up T2 - Experimental and Therapeutic Medicine TI - Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up UR - https://doi.org/10.3892/etm.2017.4229 VL - 13 ER -